Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you lose your shirt here? otherwise i would suggest investing your energy, time, and money elsewhere. otherwise what’s the point. no ROI with your approach. jmho.
I"m saying the short traders are losing confidence.
Therapeutic Solutions International was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 148,600 shares, a drop of 45.4% from the March 15th total of 272,300 shares. Based on an average daily trading volume, of 39,779,500 shares, the days-to-cover ratio is presently 0.0 days.
Yes. Let's hope this turns into to real revenues and profits!!!! The companies fundamentals look pretty good.
You haven't done your DD.
Patience is a Virtue. When the Phase 3 trial results are released, TSOI will breath a new life. Patience. And ignore the bashers.
More dilution coming. I have a large limit order in for $2
Is this fancy language for another R/S ???
Capital Reduction by Reduction of Nominal Value
The Board proposes to reduce the nominal value of the Company's share capital from CHF 56'163'348.00 to CHF 1'404'083.70 by reducing the nominal value of each share from CHF 4.00 to CHF 0.10. This technical adjustment comes as the share currently quotes at a price below its par value. This situation presents practical implications, including limiting the Company's ability to raise capital. The number of outstanding shares, as well as shareholders' financial and patrimonial rights, will not be affected by the reduction in par value. The modification of the share capital shall render the capital band provisions under the Articles of Association void.
PSRHF looks very promising with the latest news! But why is iHUB so slow? Do they have some down servers?
This is simply a waiting game!
Therapeutic Solutions International Files Patent on “Facilitating Effects” of JadiCells on Gene Therapy Mediated Cell Differentiation
https://www.businesswire.com/news/home/20240226116362/en/Therapeutic-Solutions-International-Files-Patent-on-%E2%80%9CFacilitating-Effects%E2%80%9D-of-JadiCells-on-Gene-Therapy-Mediated-Cell-Differentiation
TSOI hit 17 cents on 2/26/21. Let's do that again! I don't care if it is on hype or real facts. I'll take that PPS.
I think I'll be the WON laughing on my trip to the bank, not you.
When this thing pops to 10 cents on FDA news, everyone is going to posting... "What the F"
Major owner of THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. just picked up 10,000,000 shares
Timothy G Dixon, a major owner of THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. and THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.'s President & CEO and a director of the company, recently acquired 10,000,000 shares of the company. The buys took place at $0.00 per share, on February 26, 2024. Dixon now owns 368,993,103 shares of the company. Dixon operates out of Oceanside, CA.
I've placed my limit order in to buy at 1.50 Patience.
Unfortunately the failed trial with NIH has spoiled aviptadil IMO. And without the FDA backing this is going nowhere. Hope they prove me wrong.
All the talk about NASDAQ was b.s. I'm sure they have been diluting the crap out of this to pay their high salaries and bonuses. Which means another r/s may be in the making in 2025 (or earlier).
The simple truth is, this company does not have a product that can generate reasonable revenues. It's always been one big pipe dream. FDA approval via COVID was the one big crap shoot with high profit potential. It's gone now.
I'm just waiting for the R/S.
Wow. Clay Trader sure blew that call on 10/19/20.
Going forward... Zacks has OSUR on it's "Buy" list for stocks under 10 bucks. That's a good sign.
Transaction Date Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Details
1/18/2024 Phillip Md Et Al Frost CEO Buy 400,000 $0.97 $388,000.00
1/17/2024 Jane Ph D Hsiao Vice Chairman Buy 150,000 $0.95 $142,500.00
1/16/2024 Phillip Md Et Al Frost CEO Buy 1,000,000 $0.95 $950,000.00
1/11/2024 Phillip Md Et Al Frost CEO Buy 511,531 $0.94 $480,839.14
And whoever made that bearish assessment is probably shorting the stock.
SOBR has been doing a painful (for the SH) reverse split once every two years or so. Two years will be up again this April, so I see another R/S this year. Not good.
Elias A Zerhouni Vice Chairman wouldn't be investing $511,779.00 at .93 if their wasn't the believe that the price would go higher.
Transaction Date Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Details
1/5/2024 Elias A Zerhouni Vice Chairman Buy 550,300 $0.93 $511,779.00
1/5/2024 Richard C Pfenniger Jr Director Buy 25,000 $0.94 $23,500.00
1/5/2024 Steven D Rubin VP Buy 10,000 $0.87 $8,700.00
11/13/2023 Richard C Pfenniger Jr Director Buy 25,000 $1.30 $32,500.00
11/10/2023 Jane Ph D Hsiao Vice Chairman Buy 100,000 $1.27 $127,000.00
11/10/2023 Steven D Rubin VP Buy 10,000 $1.30 $13,000.00
11/9/2023 Phillip Md Et Al Frost CEO Buy 500,000 $1.28 $640,000.00
I was in Houston in 1984. Nice town. GLTU on your investments.
Reversion to the Mean. This will rebound. Oversold (undervalued) here. This is a great short term buy opportunity.
Are you really caring for 3 babies? I lived in TX when I had a job at Exxon downtown Houston. 20 years ago.
Hope you are right. I've gotten burned on biotechs during covid due to FDA corruption (and bad decisions on my part).
Did anyone figure out what caused that pop to $10? It's easy to say market manipulation, but has anyone specifically figured out what happened there?
The FDA never tested the current mRNA vaccine. They just tweaked it for the current variant with no clinical trials. Even though it has been proven that their vaccine causes heart attacks and other heart issues with the young. Very sloppy and unprofessional IMO. Yet they will raise the bar of standard off-the-charts for Revives drug. The FDA is corrupt and they are bought off by Big Pharm. Until Congress gets involved, it will be more of the same for decades to come. We might need a hard ass like Trump to fix this. For better or worse.
There was a R/S on 9/30/19 (1 for 50). I will wait for the aftermath to settle down after the next R/S before getting in here.
Yaa, very quiet. I was hoping for a decision by now.
Pegs,
IMO I think working through India is your best bet. I think we are years away in the USA before aviptadil is FDA approved for anything.
What is the ticker symbol for that EV battery stock? I'll put it on my watch list.
Take care, and I wish you the best. Keep fighting the fight!
Not sure I understand your point. $1.16 is $1.16. Good for some SH.
For me, now I have to swing trade this at a higher range. Buy at 1.10, take profits at s 1.16
I don't think so. I suspect we'll see another pull back. Profit taking.
The judge will make a decision on the merger with Spirit any day now. If the judge lets the merger go through, the shorts will have to quickly cover resulting in a squeeze.
From a technical analysis (TA) point of view, I see JBLU currently overvalued, hence a 'pull back' will occur (profit taking).
What the near-term future holds after that depends on the judges decision IMO. Which could be any day now. But thus far his hints have leaned in favor of JBLU. We'll see.
Trial over JetBlue's Spirit merger ends with US judge mulling options
Tue, December 5, 2023
https://finance.yahoo.com/news/jetblue-trials-end-urges-judge-151836412.html?fr=sycsrp_catchall
Federal Judge Leans Towards Approval of JetBlues Acquisition of Spirit Airlines
December 6, 2023
On December 6, 2023, a significant development unfolded in the aviation industry as a federal judge leaned towards granting approval for JetBlue’s proposed acquisition of Spirit Airlines, valued at a staggering $3.8 billion. Despite the Justice Department’s efforts to impede the deal, the judge hinted that it could move forward under the condition that JetBlue divests additional assets to address potential antitrust concerns.
While the Justice Department argued vehemently that the merger would result in inflated prices and reduced flight options, the judge expressed reservations about obstructing a deal within an industry that is constantly evolving and facing unprecedented challenges in the post-COVID era. This dynamic environment presents both unique opportunities and hurdles that must be carefully considered.
The final verdict ultimately rests in the hands of the judge presiding over the non-jury trial in Boston, who holds the authority to shape the future of this pivotal acquisition.